简介:Severeacuterespiratorysyndrome(SARS)emergedin2002asasevereandhighlycontagiousinfectiousdiseasethatrapidlyspreadtoanumberofdifferentcountries.Thecollaborativeeffortsoftheglobalscientificcommunityhaveprovided,withinashortperiodoftime,substantialinsightsintothemolecularbiologyandimmunologyofSARS-CoV.Althoughtheoutbreakhasbeencontained,thereiscontinuousconcernthatthevirusmayresurfaceintothehumanpopulationthroughseasonalchanges,animalreservoirsorlaboratoryaccidents.TheseveremorbidityandmortalityassociatedwithSARSmakeitimperativethataneffectivevaccinebedevelopedtopreventreemergenceandepidemicsinthefuture.Cellular&MolecularImmunology.2005;2(2):101-105.
简介:DevelopingawidelyadaptableAIDSvaccineisthegoalofscientistswhofightagainstglobalproliferationofthedeadlydisease.NoW,somearefocusingtheirstudyonChina,believingthatthecountrymaybetheperfectpartnerforacollaborationinvaccineresearch.AninternationalAIDSvac...
简介:AbstractGlioblastoma (GBM) is the most common primary malignancy of the central nervous system in adults. The prognosis for late-stage glioblastoma (World Health Organization grade IV astrocytic glioma) is very poor. Novel treatment options are sought after and evaluated by clinicians and researchers, and remarkable advances have been made in surgical techniques, radiotherapy, and chemotherapy. However, the treatment of glioblastoma remains extremely difficult and it can extend the lives of patients by only a few months. There has been notable progress in the field of immunotherapy, particularly with the use of tumor vaccines, for treating glioblastoma; especially peptide vaccines and cell-based vaccines such as dendritic cell vaccines and tumor cell vaccines. However, the results of the current clinical trials for vaccination are not satisfactory. This article reviews the progress in the development of vaccines for glioblastoma.
简介:Inordertoinvestigatetheimmtmogenicityofthecontrolled-releasemicroencapsulatedhepatitisBvaccineinmice,polyethyleneglycol-poly-dl-lactide(PELA)microsphereswithentrappedHSsAgwerepreparedbydoubleemulsionW/O/Wbasedonsolventextractionmethods.BALB/cmicewereimmunizedwiththeencapsulatedvaccinebyoralfeedingorinjection.Bloodsampleswerecollectedat8^th,10^th,14^thand24^thweeks,respectively,andthelevelsofantibodyresponseweredetectedbyEI.ISA.Itwasfoundthatthescanningelectronmicroscopyshowedthepreparedmicrosphereshadsmoothandsphericalsurface,suitableforvaccinedelivery.Twogroupsofmiceorallyfedwiththeencapsulatedorconventionalrecombinantvaccines,respectively,theresereshowednoobviousdifferenceintheIgGlevels.At14^thweek,thegroupinjectedwithasingledoseofencapsulatedvaccinehadasimilarlevelofIgGresponsetothegroupinjectedwithtwodosesoftherecombinationvaccine.At24^thweek,theIgGlevelsofthegroupinjectedwithtwodosesofencapsulatedvaccinewerehigherthanthoseofthegroupinjectedwithtwodosesoftherecombinationvaccine.ItconcludesthatControlled-releasemicroencapsulatedhepatitisBvaccinepossessesthefeatureofslowlyreleasinginv/voandlongtimesimmtmogenicity.
简介:AbstractSevere fever with thrombocytopenia syndrome (SFTS), caused by a novel identified bunyavirus SFTS virus (SFTSV), was an emerging viral infectious disease that was firstly reported in China. There are no licensed vaccines and therapeutics against SFTSV currently. B-Propiolactone (BPL) inactivated whole virions of SFTSV strain AH12 were prepared as experimental vaccine in different antigen dose with or without Al(OH)3 adjuvant. The experimental SFTS vaccine was a satisfying immunogen, which could efficiently trigger the development of high levels of SFTSV NP-specific IgG antibodies and neutralizing antibodies against SFTSV Strain HB29 in BALB/c and C57/BL6 mice, and could induce SFTS virus-specific cellular immune responses to a certain extent. A single dose of vaccine was immunogenically insufficient in BALB/c mice; the second and third dose resulted in significant boost in antibody response. The use of Al(OH)3 adjuvant resulted in higher antibody titers. The mediate-dose of vaccine could induce as high and equivalent level of antibody titer as that of high-dose. The experimental SFTS vaccine in mediate-and high antigen dose with adjuvant resulted in solid protection of C57/BL6 mice against wild-type SFTSV challenge with markedly accelerated virus clearance from blood and spleen compared with controls. The experimental SFTS vaccine prepared in this study could efficiently elicit virus specific humoral and cellular immune responses in both BALB/c and C57/BL6 mice, and could protect C57/BL6 mice against SFTS virus challenge. These results supplied evidence that inactivated vaccine was a promising vaccine candidate for the prevention of SFTSV infection.
简介:AbstractVaccines are one of the biggest successes in modern history and are particularly important in light of the multiple ongoing epidemics. Recently, vaccines have protected peoples’ health and lives around the world during the coronavirus disease 2019 pandemic. Different types of vaccines have their own characteristics and advantages and are used in the context of different epidemics. Responses to vaccination are also different, and can include adverse reactions and absent responses. These individual differences are thought to be influenced by host genes. In this review, we first discuss vaccine types and characteristics. Second, we discuss different responses to vaccination, primarily focusing on the association between genetic variation and inter-individual differences.
简介:Anoveltuberculosis(TB)genevaccinecontainingmousegranulocytemacrophage-colonystimulatingfactor(mGM-CSF)andaTBantigen(Ag85A)wasdevelopedinthisstudy.ThegenesencodingAg85AandmGM-CSFwereamplifiedbyPCRrespectivelyfromtheAg85A-containingpBSby5andpC-mGM-CSF.ThegeneswerethenclonedintotwodifferentpolylinkersitesofplasmidpIRES,forminganovelTBgenevaccineconstructpI85AGM.FollowingtransfectionofpI85AGMplasmidinto7721celllinebyLipofectamineTM,theexpressionofAg85AandGM-CSFproteinswasidentifiedbyWesternblottingorRT-PCR.ThenBalb/cmicewereinoculatedwiththerecombinantpI85AGM,pI85A,pIGMorplasmidalone,respectively.TheactivitiesofCTL,NKcellsandtheAg85A-stimulatedproliferationofspleencellsweremeasuredbyMTTmethod.TheserumantibodyagainstAg85AwasdetectedbyELISA.TheresultsshowedthattheAg85AandGM-CSFproteinscouldbeexpressedin7721celllineandtheactivityofCTLsandtheproliferationofspleencellsweresignificantlyincreasedinthepI85AGM-immunizedmice,indicatingthatthepI85AGM-immunizedmicecouldgeneratespecificimmuneresponsestoAg85A.Thisstudymightprovidepossibilityfordevelopingnovelanti-TBgenevaccine.
简介:<正>ThemostrecentreportontheobesityepidemicbytheU.S.InstituteofMedicine(IOM)haspaintedableakpictureofrealityintheU.S.Itreportsthattwothirdofadultsandalmostonethirdofchildrenareeitheroverweightorobesebyanycountsofmeasures.Situationsinothercountriesdonotseemoptimisticeither.AccordingtotheWorldHealthOrganization(WHO),thenumbersofobesechildrenhaveincreasedduringthelastdecadetoanestimated35millionindevelopingcountriesand8millionindevelopedcountries
简介:无
简介:AIM:TOinvestigatetheimmunogenicityofcandidateDNAvaccineagainsthepatitisCvirus(HCV)deliveredbytwoplasmidsexpressingHCVenvelopeprotein1(El)andenvelopeprotein2(E2)antigensrespectivelyandtostudytheeffectofCpGadjuvantonthiscandidatevaccine.METHODS:RecombinantplasmJdsexpressingHCVEIandE2antigensrespectivelywereusedtosimultaneouslyinoculatemicewithorwithoutCpGadjuvant.AntiserawerethencollectedandtJtersofantJ-HCVantibodieswereanalyzedbyELISA.Onemonthafterthelastinjection,animalsweresacrificedtopreparesingle-cellsuspensionofsplenocytes.ThesecellsweresubjectedtoHCVantigenspecificproliferaionassaysandcytokinesecretionassaystoevaluatethecellularimmuneresponsesofthevaccinatedanimals.RESULTS:AntibodyresponsestoHCVEIandE2antigensweredetectedinvaccinatedanimals.AnimalsreceivingCpGadjuvanthadslightlylowertitersofanti-HCVantibodiesinthesera,whilethesplenocytesfromtheseanimalsshowedhigherHCV-antigenspecificproliferation.Analysisofcytokinesecretionfromthesplenocyteswasconsistentwiththeaboveresults.Whilenoantigen-specificIL-4secretionwasdetectedforallvaccinatedanimals,HCVantigen-specificINF-γ,secretionwasdetectedforthesplenocytesofvaccinatedanimals.CpGadjuvantenhancedthesecretionofINF-γ,butdidnotchangetheprofileofIL-4secretion.CONCLUSION:VaccinationofmicewithplasmidsencodingHCVE1andE2antigensinduceshumoralandcellularimmuneresponses.CpGadjuvantsignificantlyenhancesthecellularimmuneresponse.
简介:Oligodeoxynucleotides(ODN)containingunmethylatedCpGdinucleotidesincontextsofuniquesequence(CpGmotifs)isactiveasadjuvantininductionofcellularandhumoralimmuneresponsesinyoungmice.Todate,thereareonlylimitedreportsabouteffectofCpGODNonimmuneresponsesagainsthepatitisB(HB)infectioninagedmice.Ourstudiesdemonstratedthereweresignificantincreasesinsecretingoftotalanti-HBIgG,IgG1andIgG2a,aswellasofIL-12andIFN-γ,whenCpGODNswereinjectedtogetherwithhepatitisBantigeninagedmice.Moreover,CpGODNcouldstimulateproliferationofspleenlymphocytesinadose-dependentmanner.Takentogether,theresultsweobtainedindicatethattheaddingofCpGODNintothevaccineantigenmightbeusefulindevelopmentofmoreeffectivevaccinationforinducinganti-HBvirusresponsesintheelderly.
简介:ThepurposeofthisstudywastotesttheeffectivenessofsourcevirusstrainforthemanufactureoftheinactivatedSARSvirusvaccine,andestablishanexperimentalmethodandpreliminarystandardforpotencyevaluation.MiceweredividedintogroupsforbeingimmunizedwithcorrespondingseriallydilutedexperimentalSARSvirusinactivatedvaccine.Andtherabbitswereimmunizedwithundilutedvaccine.ChallengeassaywasconductedwithaheterologousSARSvirus.Andtheneutralizationantibodywasdeterminedwithplaquereductionneutralizationtest(PRNT),towhichtheneutralizationantibodyintheconvalescentserumofSARSpatientswascompared.Theexperimentalvaccineviralstrainswereprovedtobesuitableformanufacturingthevaccine.Miceimmunizedbyvaccinesofserialdilutionswereabletoelicitneutralizingantibody.Theantibodytiterfrommiceimmunizedwiththeundilutedvaccinecouldreachupto1:495.2,whilethoseofrabbitsimmunizedwiththeundilutedvaccinecouldreachaGMTof55.0-79.9.ThecapabilityoftheantibodytoneutralizethevirusfromGuangdongismoreefficientthanthatfromBeijing.TheGMTofneutralizingantibodyinSARSconvalescentslivinginsouthandnorthChinarangedfrom50.12to54.95,andthetitersofconvalescentsfromnorthChinawerehigherthanthosefromsouthChina.Miceandrabbitsusedasthemodelforevaluationofpotencyareofsensitivity,andthetestisofreproducibility.Thecandidatechallengeviralstrainsshowedarelativelyconsistenteffectonevaluatingantibodiesproducedbyvariousbatchesanddifferentvaccine-sourcestrains,hencetheycanbeusedtoevaluatepotencyofthevaccine.Themethodfortestingthevaccinepotencyandtheevaluationstandardwasestablishedpreliminarily.
简介:Objective:Toamplifyantigengenesfrompatientswithhumanimmunodeficiencyvirustype1(HIV-1)inGuangdongProvinceforcandidateAIDSvaccinedesign.Methods:Viralnucleicacidwasisolatedfrom10HIV-1infectedindividuals'peripheralbloodcollectedduring1995-2000inGuangdongProvince.Theviralgagp24geneandenvgp120genewereamplifiedbynested-PCRandsequenced.ThehomologiesamongHIV-1isolateswerecomparedwithHIV-BLAST.Results:Among10HIV-1isolates,ninearehomologoustovirusesofsubtypeB,andoneishomologoustovirusesofsubtypeE.Conclusion:SubtypeBvirusesofHIV-1arepredominantlypresentinGuangdongProvince.